SG Americas Securities LLC lessened its stake in United Therapeutics Co. (NASDAQ:UTHR) by 19.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,118 shares of the biotechnology company’s stock after selling 1,958 shares during the quarter. SG Americas Securities LLC’s holdings in United Therapeutics were worth $912,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. NuWave Investment Management LLC increased its holdings in United Therapeutics by 13,112.5% in the 1st quarter. NuWave Investment Management LLC now owns 1,057 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 1,049 shares in the last quarter. Focused Wealth Management Inc acquired a new stake in United Therapeutics during the 4th quarter worth $139,000. SeaCrest Wealth Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth $178,000. JOYN Advisors Inc. acquired a new stake in United Therapeutics during the 4th quarter worth $201,000. Finally, HL Financial Services LLC acquired a new stake in United Therapeutics during the 4th quarter worth $217,000. 99.18% of the stock is owned by institutional investors.
Shares of UTHR opened at $103.60 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.81 and a current ratio of 5.13. The firm has a market cap of $4.56 billion, a price-to-earnings ratio of 9.51, a price-to-earnings-growth ratio of 26.78 and a beta of 1.33. United Therapeutics Co. has a 52-week low of $100.57 and a 52-week high of $152.55.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, beating the consensus estimate of $3.62 by $1.95. The firm had revenue of $389.20 million for the quarter, compared to analysts’ expectations of $393.96 million. United Therapeutics had a net margin of 27.74% and a return on equity of 26.68%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.61 EPS. analysts forecast that United Therapeutics Co. will post 13.04 earnings per share for the current fiscal year.
UTHR has been the topic of several recent research reports. BidaskClub cut shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 1st. Credit Suisse Group lowered their target price on shares of United Therapeutics from $108.00 to $104.00 and set a “neutral” rating on the stock in a research note on Thursday, May 3rd. Barclays reaffirmed an “underweight” rating and set a $105.00 target price (down previously from $115.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, ValuEngine cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $134.00.
In other news, CEO Martine A. Rothblatt sold 21,512 shares of the business’s stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $112.55, for a total transaction of $2,421,175.60. Following the transaction, the chief executive officer now owns 21,652 shares of the company’s stock, valued at approximately $2,436,932.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 301 shares of the business’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $110.48, for a total transaction of $33,254.48. Following the transaction, the chief executive officer now directly owns 21,652 shares in the company, valued at approximately $2,392,112.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,046 shares of company stock worth $19,506,251. Corporate insiders own 8.20% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.